Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.78
(-0.24%)
CNY 20.78
(-0.24%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 330.72 Million CNY | 37.07% |
| 2022 | 241.27 Million CNY | 24.61% |
| 2021 | 193.62 Million CNY | 3.39% |
| 2020 | 187.27 Million CNY | 9.7% |
| 2019 | 170.71 Million CNY | 3.68% |
| 2018 | 164.65 Million CNY | 135.05% |
| 2017 | 70.05 Million CNY | -37.34% |
| 2016 | 111.79 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 108.5 Million CNY | 4.65% |
| 2024 Q1 | 100.44 Million CNY | 53.6% |
| 2024 Q2 | 108.3 Million CNY | 7.82% |
| 2023 Q4 | 65.39 Million CNY | -55.62% |
| 2023 FY | 330.72 Million CNY | 37.07% |
| 2023 Q3 | 147.36 Million CNY | 149.82% |
| 2023 Q2 | 58.98 Million CNY | 0.03% |
| 2023 Q1 | 58.97 Million CNY | 130.6% |
| 2022 Q3 | 25.23 Million CNY | -73.16% |
| 2022 FY | 241.27 Million CNY | 24.61% |
| 2022 Q2 | 94.02 Million CNY | 75.99% |
| 2022 Q1 | 53.42 Million CNY | 39.14% |
| 2022 Q4 | 25.57 Million CNY | 1.34% |
| 2021 Q2 | 58.12 Million CNY | 43.76% |
| 2021 Q1 | 40.43 Million CNY | 71.03% |
| 2021 Q4 | 38.39 Million CNY | -32.24% |
| 2021 Q3 | 56.66 Million CNY | -2.51% |
| 2021 FY | 193.62 Million CNY | 3.39% |
| 2020 Q1 | 59.26 Million CNY | 83.93% |
| 2020 FY | 187.27 Million CNY | 9.7% |
| 2020 Q4 | 23.63 Million CNY | -41.86% |
| 2020 Q3 | 40.65 Million CNY | -36.18% |
| 2020 Q2 | 63.71 Million CNY | 7.51% |
| 2019 Q4 | 32.22 Million CNY | -40.99% |
| 2019 Q3 | 54.59 Million CNY | 0.0% |
| 2019 FY | 170.71 Million CNY | 3.68% |
| 2018 FY | 164.65 Million CNY | 135.05% |
| 2017 FY | 70.05 Million CNY | -37.34% |
| 2016 FY | 111.79 Million CNY | 0.0% |